ANIKA THERAPEUTICS, INC.

(ANIK)
  Report
Real-time Estimate Cboe BZX  -  05/26 01:31:04 pm EDT
21.73 USD   +0.60%
05/20SECTOR UPDATE : Health Care Stocks Gain Premarket Friday
MT
05/20SECTOR UPDATE : Health Care
MT
05/20Anika Therapeutics Says FDA Approves X-Twist System for Soft Tissue Repair
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Anika Therapeutics : UBS Starts Anika Therapeutics at Neutral With $46 Price Target

07/16/2021 | 09:45am EDT


© MT Newswires 2021
All news about ANIKA THERAPEUTICS, INC.
05/20SECTOR UPDATE : Health Care Stocks Gain Premarket Friday
MT
05/20SECTOR UPDATE : Health Care
MT
05/20Anika Therapeutics Says FDA Approves X-Twist System for Soft Tissue Repair
MT
05/20Anika Receives FDA 510(k) Clearance for the X-Twist™ Knotless Fixation System, Ex..
GL
05/20Anika Receives FDA 510(k) Clearance for the X-Twist Knotless Fixation System, Expanding..
CI
05/20Anika Therapeutics Gets FDA OK for X-Twist Knotless Fixation System
DJ
05/13Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
05/09Anika to Participate in the UBS Global Healthcare Conference 2022
AQ
05/06Tranche Update on Anika Therapeutics, Inc.'s Equity Buyback Plan announced on May 2, 20..
CI
05/06ANIKA THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION A..
AQ
More news
Analyst Recommendations on ANIKA THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 154 M - -
Net income 2022 -11,0 M - -
Net Debt 2022 - - -
P/E ratio 2022 -28,5x
Yield 2022 -
Capitalization 314 M 314 M -
Capi. / Sales 2022 2,03x
Capi. / Sales 2023 1,85x
Nbr of Employees 297
Free-Float 98,2%
Chart ANIKA THERAPEUTICS, INC.
Duration : Period :
Anika Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ANIKA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 21,60 $
Average target price 37,50 $
Spread / Average Target 73,6%
EPS Revisions
Managers and Directors
Cheryl Renee Blanchard President, Chief Executive Officer & Director
Michael L. Levitz Chief Financial Officer, Treasurer & EVP
Jeffery S. Thompson Chairman
Mira Leiwant VP-Quality, Regulatory & Clinical Affairs
Steven W. Ek Vice President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
ANIKA THERAPEUTICS, INC.-41.31%314
CSL LIMITED-5.89%93 252
SAMSUNG BIOLOGICS CO.,LTD.-6.98%46 658
BIOGEN INC.-15.66%29 636
WUXI BIOLOGICS (CAYMAN) INC.-42.41%28 644
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-30.66%21 435